Business Context and Reporting Period
Company: Supernus Pharmaceuticals, Inc. (SUPN)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal Year Ended December 31, 2025
Business Overview: Supernus is a biopharmaceutical company focused on developing and commercializing products for central nervous system (CNS) diseases, including ADHD, Parkinson's Disease, epilepsy, and postpartum depression (PPD).
Key Event: On July 31, 2025, the Company completed the acquisition of Sage Therapeutics, Inc. (Sage), adding ZURZUVAE (zuranolone) to its portfolio. The transaction included a cash payment of approximately $561 million and contingent value rights (CVRs) valued at approximately $234 million.
Key Financial Metrics
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Total Revenues | $718.95 million | $661.82 million | +9% |
| Net Product Sales | $626.54 million | $637.70 million | -2% |
| Net Earnings (Loss) | $(38.55) million | $73.87 million | Turned to Loss |
| Operating Earnings (Loss) | $(62.28) million | $81.67 million | Turned to Loss |
| Net Cash from Operating Activities | $47.33 million | $171.95 million | -73% |
| Cash and Cash Equivalents | $128.45 million | $69.33 million | +85% |
| Total Assets | $1,452.65 million | $1,368.07 million | +6% |
Revenue Composition (2025): Qelbree (49%), GOCOVRI (23%), Trokendi XR (7%), APOKYN (8%), Oxtellar XR (6%), ONAPGO (3%), and Collaboration Revenue from ZURZUVAE ($53.0 million).
Material Changes vs. Prior Period
- Acquisition Impact: The Sage Acquisition drove a significant increase in Selling, General, and Administrative (SG&A) expenses ($485.6 million in 2025 vs. $321.6 million in 2024), primarily due to transaction costs ($10.0 million), post-combination employee expenses ($38.3 million), and accelerated share-based compensation ($25.0 million).
- Product Performance:
- Qelbree: Sales increased 26% to $304.7 million, driven by higher volume and price.
- GOCOVRI: Sales increased 12% to $146.8 million.
- ONAPGO: Launched in Q2 2025, generating $17.3 million in sales. However, supplier constraints in Q4 2025 limited ability to meet demand, impacting revenue.
- Generic Erosion: Sales of Oxtellar XR (-59%) and Trokendi XR (-33%) declined due to generic competition following loss of exclusivity.
- Contingent Consideration: A loss of $25.4 million was recorded in 2025 (vs. a gain of $6.1 million in 2024) due to the revaluation of Sage CVRs following regulatory approval of ZURZUVAE for MDD in Japan.
- Tax Position: The Company recorded an income tax benefit of $10.5 million in 2025 compared to an expense of $24.0 million in 2024, driven by the pre-tax book loss.
Guidance, Outlook, Risks, and Unusual Items
- Outlook: Management expects continued profitability in future years but anticipates significant variability due to market pressures, generic competition, and funding requirements for R&D and new product launches (ONAPGO, ZURZUVAE).
- Supply Chain Risks: ONAPGO faces supply constraints due to reliance on a single-source supplier in Europe. A second supplier is expected to begin supply in 2027. New patient initiation was paused in Q4 2025 but resumed in February 2026.
- Legal Proceedings:
- Sage Litigation: Pending securities class action, SEC investigation regarding zuranolone MDD NDA, and consolidated derivative litigation against former Sage officers.
- Patent Litigation: Multiple Paragraph IV lawsuits filed against generic manufacturers for Qelbree (viloxazine), with trials expected in 2027.
- Antitrust: Ongoing litigation regarding APOKYN alleging antitrust violations.
- Regulatory Risks: ZURZUVAE carries a boxed warning for driving impairment. The Company faces potential pricing pressures from the Inflation Reduction Act (IRA) and potential changes in Medicaid reimbursement policies.
- Unusual Items: The 2025 net loss was significantly impacted by non-recurring acquisition-related costs and the fair value adjustment of contingent consideration liabilities.
Investor Verification Checklist
- ONAPGO Supply Resolution: Verify the status of the second supplier qualification and the impact of the Q4 2025 supply pause on full-year 2026 revenue projections.
- Sage Integration Costs: Confirm the run-rate of SG&A expenses post-acquisition to assess the sustainability of operating margins.
- Contingent Consideration Liability: Monitor the fair value of the Sage CVRs, which could range from $0 to $234 million, and the impact of future ZURZUVAE sales milestones on the income statement.
- Generic Defense: Track the progress of patent litigation for Qelbree and the potential impact of generic entry on the Company's primary revenue driver.
- Liquidity Position: Assess the sufficiency of the $308.7 million in cash and marketable securities to fund operations and potential milestone payments without dilutive equity raises.